Grünenthal acquires global rights for Qutenza®

Aachen (ots) - Grünenthal, the science-focused pharmaceutical
company based in Germany, announced today that it has acquired
additional global commercial rights for the dermal pain patch
Qutenza® (8% capsaicin) from Acorda Therapeutics, Inc (USA).
Grünenthal is now the sole owner of Qutenza® worldwide, including the
US, Latin America, Asia and Australia. Grünenthal had already
acquired exclusive commercial rights for Europe, Middle East and
Africa in December 2016.

"As a leader in pain research and management, we're dedicated to
providing solutions for patients with high unmet medical needs.
Qutenza® is a perfect strategic fit, as it complements our existing
pain portfolio and is a real alternative to the current standard of
care," says Gabriel Baertschi, Grünenthal's Chief Executive Officer.

Qutenza® is a highly effective pain product. A single, 1-hour,
localised treatment with this patch may provide at least 3 months of
relief from for example post-shingles nerve pain. Grünenthal will aim
to make Qutenza® available to patients worldwide. In territories
where the company does not have a presence of its own such as Asia
and Australia, Grünenthal will look to partner or out-license
Qutenza®.

Grünenthal continues executing its growth strategy and has been
expanding its pain portfolio by a series of acquisitions including
European rights to Nexium®, the global (ex US and Japan) rights to
Vimovo® and global (ex Japan) rights to Zomig®. The company has
signed deals with a total value of more than US$ 1.3 billion since
2016.

About Qutenza®

Qutenza® (capsaicin) 8% patch is approved in the US for the
management of neuropathic pain associated with postherpetic
neuralgia. A single, 1-hour, localized treatment with Qutenza® may
provide at least 3 months of relief from for example post-shingles
nerve pain (PHN). In Europe, Qutenza® is approved by the European
Medicines Agency for the treatment of peripheral neuropathic pain in
adults, either alone or in combination with other pain medicines. The
8% capsaicin patch delivers a high dose of capsaicin directly to the
damaged nerves in the skin that are the source of neuropathic pain.
Applied to the area of pain, the capsaicin reduces the spontaneous
activity and consequently reduces the neuropathic pain intensity.
Important safety information can be found here: www.qutenza.com (for
US) and http://ots.de/yYetCA (for Europe)

About Grünenthal

Grünenthal is an entrepreneurial, science-based pharmaceutical
company specialized in pain, gout and inflammation. Our ambition is
to deliver four to five new products to patients in diseases with
high unmet medical need by 2022 and become a EUR 2 bn company. We are
a fully integrated research & development company with a long track
record of bringing innovative pain treatments and state-of-the-art
technologies to patients. By sustainably investing in our R&D above
the industrial average, we are strongly committed to innovation.

Grünenthal is an independent, family-owned company headquartered
in Aachen, Germany. We are present in approx. 30 countries with
affiliates in Europe, Latin America and the US. Our products are sold
in more than 100 countries and approx. 5,200 employees are working
for Grünenthal worldwide. In 2017, Grünenthal achieved revenues of
approx. EUR 1.3 bn. More information: www.grunenthal.com Follow us
on: LinkedIn: Grunenthal Group Twitter: @grunenthalgroup Instagram:
gruenenthal

For further information, please contact:
Stepan Kracala, Head Global Communications
Tel.: +49 241 569-1335, Stepan.Kracala@grunenthal.com
Grünenthal GmbH, 52099 Aachen, Germany

Kerstin Nacken, Head Editorial Management and Media Relations
Tel.: +49 241 569-2710, Kerstin.Nacken@grunenthal.com
Grünenthal GmbH, 52099 Aachen, Germany

Original-Content von: Grünenthal Group, übermittelt durch news aktuell